NOVARTIS NAM. SF 0_50
Commented by Nico Popp on May 12th, 2026 | 09:10 CEST
Biotech and the Efficiency Revolution: Why the Final Mile Matters Most for Novartis, BioNTech, and BioNxt
While biotech investors long believed that only the discovery of an entirely new molecule could pave the way for a billion-dollar exit, the current market reality paints a far more nuanced picture. Savvy investors and industry analysts are increasingly recognizing that the true bottleneck in modern medicine is no longer the discovery of active ingredients alone. Instead, the strategic focus is shifting toward bioavailability, targeted drug delivery, and improved patient compliance. This transformation is being accelerated by the looming patent cliff, which threatens the pharmaceutical industry with combined annual peak revenues of several hundred billion US dollars by 2030. We take a closer look at the market and highlight emerging opportunities.
Read
Commented by Nico Popp on August 25th, 2025 | 07:05 CEST
New research findings – Cell metabolism relevant in cancer: Roche, Novartis, and Vidac Pharma
What if cancer cells no longer grew uncontrollably, and we could target the metabolism of these cells directly? The so-called Warburg effect makes this possible. Discovered around 100 years ago by Otto Warburg, the effect describes the energy metabolism of cancer cells and shows that their metabolism differs from that of healthy cells. This opens up great opportunities for specific therapies in biotechnology. The theoretical assumption is that if the metabolism of cancer cells can be specifically disrupted, treatment will be targeted and free of side effects. Biotech start-up Vidac Pharma is fully committed to the Warburg effect. We explain what the Canadians are researching and why the technology could complement the offerings of several large pharmaceutical companies.
Read
Commented by Juliane Zielonka on March 3rd, 2022 | 13:12 CET
Cardiol, BioNTech, Novartis - Inventory at three high-flyers
Good news, this time from Cardiol Therapeutics. Both the US FDA and regulatory authorities in Brazil and Mexico have given the green light for the inclusion of patients already vaccinated against COVID-19 in the LANCER trial. The opening with respect to this patient group increases the likelihood of a speedy trial completion. The pandemic cannot be over until global efforts are made to fight the virus together. So BioNTech will build a plant in Rwanda. And Novartis, as an experienced Big Pharma giant, illustrates through its quarterly figures how valuable the pharmaceutical industry as a whole can be as an investment.
Read
Commented by Mario Hose on January 9th, 2020 | 05:50 CET
Memphasys, Merck, Novartis - Solutions for the desire to have children
Many couples around the world long for their own children, but for many people, family planning by natural means is not possible. Modern medicine can help in the development of a pregnancy by means of artificial insemination, the so-called in vitro fertilisation, also known as IVF procedure. In this context, egg cells are taken from the woman and artificially fertilised with the man's sperm in the laboratory. If successful, embryos can then be transferred to the uterus. The need for artificial insemination in couples varies between 16 and 25% depending on the region - a large and global market.
Read